Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The planned Study will be a retrospective study on the effect of ACE's vs. candesartan on cardiovascular events and on health economic effects in a "real life" setting in Sweden.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ACE | Patients treated for hypertension with ACEs without CVD | ||
| Candesartan | Patients treated for hypertension with candesartan without CVD |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Investigate the risk of Cardiovascular Disease (CVD) and new onset diabetes in patients on primary hypertensive treatment with ACE or candesartan for hypertension | Time to first CV event calculated as the time (in days) between date of index prescription and date of the first registration of a CV event. Patients will be followed for min. 1 wk and up to 9 yrs (1999-2007). Median follow up time is estimated to 2 yrs. |
| Measure | Description | Time Frame |
|---|---|---|
| To investigate the risk of CVD and new onset diabetes in patients treated with specific types of ACEi or candesartan for hypertension | Time to first CV event calculated as the time (in days) between date of index prescription and date of the first registration of a CV event. Patients will be followed for min. 1 wk and up to 9 yrs (1999-2007). Median follow up time is estimated to 2 yrs. | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patient treated with ACE or candesartan in the period 1999 - 2007.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Niklas Lindarck | AstraZeneca Nordic | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Research Site | Avesta | Sweden | ||||
| Research Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 25211055 | Derived | Hasvold LP, Bodegard J, Thuresson M, Stalhammar J, Hammar N, Sundstrom J, Russell D, Kjeldsen SE. Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients. J Hum Hypertens. 2014 Nov;28(11):663-9. doi: 10.1038/jhh.2014.43. Epub 2014 Jun 26. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| To investigate the risk of hypertensive organ damage, renal failure and hyperlipidemia for patients treated with ACEi or candesartan |
| Time to first CV event calculated as the time (in days) between date of index prescription and date of the first registration of a CV event. Patients will be followed for min. 1 wk and up to 9 yrs (1999-2007). Median follow up time is estimated to 2 yrs. |
| Evaluate differences in use of health care resources, and assess the potential long term cost effectiveness | Differences in health care consumption will be estimated through models incorporating normalised costs, level of care, age, gender and study year |
| Älvdalen |
| Sweden |
| Research Site | Ängelholm | Sweden |
| Research Site | Åkersberga | Sweden |
| Research Site | Bengtsfors | Sweden |
| Research Site | Borlänge | Sweden |
| Research Site | Falun | Sweden |
| Research Site | Farsta | Sweden |
| Research Site | Fritsla | Sweden |
| Research Site | Gagnef | Sweden |
| Research Site | Gävle | Sweden |
| Research Site | Gothenburg | Sweden |
| Research Site | Grängesberg | Sweden |
| Research Site | Grycksbo | Sweden |
| Research Site | Hallstahammar | Sweden |
| Research Site | Hägersten | Sweden |
| Research Site | Hässelby | Sweden |
| Research Site | Hedemora | Sweden |
| Research Site | Helsingborg | Sweden |
| Research Site | Henån | Sweden |
| Research Site | Höllviken | Sweden |
| Research Site | Jarfalla | Sweden |
| Research Site | Kil | Sweden |
| Research Site | Kolbäck | Sweden |
| Research Site | Kolsva | Sweden |
| Research Site | Köping | Sweden |
| Research Site | Leksand | Sweden |
| Research Site | Lidköping | Sweden |
| Research Site | Likenäs | Sweden |
| Research Site | Limhamn | Sweden |
| Research Site | Ludvika | Sweden |
| Research Site | Malmö | Sweden |
| Research Site | Malung | Sweden |
| Research Site | Mora | Sweden |
| Research Site | Munka-Ljungby | Sweden |
| Research Site | Norberg | Sweden |
| Research Site | Sala | Sweden |
| Research Site | Säter | Sweden |
| Research Site | Skanör | Sweden |
| Research Site | Skepplanda | Sweden |
| Research Site | Skinnskatteberg | Sweden |
| Research Site | Skogås | Sweden |
| Research Site | Skoghall | Sweden |
| Research Site | Skövde | Sweden |
| Research Site | Skultuna | Sweden |
| Research Site | Smedjebacken | Sweden |
| Research Site | Stockholm | Sweden |
| Research Site | Stora Höga | Sweden |
| Research Site | Sunnansjö | Sweden |
| Research Site | Sunne | Sweden |
| Research Site | Svärdsjö | Sweden |
| Research Site | Trollhättan | Sweden |
| Research Site | Upplands Vasby | Sweden |
| Research Site | Uppsala | Sweden |
| Research Site | Vansbro | Sweden |
| Research Site | Västerås | Sweden |
| ID | Term |
|---|---|
| D006973 | Hypertension |
| D002318 | Cardiovascular Diseases |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
Not provided
Not provided